- 专利标题: Macrocyclic MCL-1 Inhibitors and Methods of Use
-
申请号: US17649906申请日: 2022-02-03
-
公开(公告)号: US20230183261A1公开(公告)日: 2023-06-15
- 发明人: Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
- 申请人: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
- 申请人地址: US IL North Chicago
- 专利权人: AbbVie Inc.,AbbVie Deutschland GmbH & Co. KG
- 当前专利权人: AbbVie Inc.,AbbVie Deutschland GmbH & Co. KG
- 当前专利权人地址: US IL North Chicago
- 分案原申请号: US15998789 2018.08.15
- 主分类号: C07D495/16
- IPC分类号: C07D495/16 ; C07D495/18 ; A61K45/06 ; C07D495/22 ; C07D491/18 ; A61K31/519 ; C07D491/22 ; A61P35/00 ; A61P35/02
摘要:
The present disclosure provides for compounds of formula (I)
wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
信息查询